HK2 and central nervous system cancer: Similar to the cohort I, the levels of HK2 and NOX2 were elevated in patients with G3 glioma (G3) relative to those in G1 and G2 gliomas (G1, G2) in the cohort II (Table S2 and Figure S4a).